GR1802
Phase 3Small molecule
GR1802 is one of 126 small molecule programs targeting Sinusitis. It is currently in Phase 3.
5
Indications
8
Total Trials
5
Active Trials
125
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1050 competitors in Asthma
#DrugCompanyPhaseTrials
1GR1802
GGenrix (Shanghai) Biopharmaceutical Co., Ltd.
Phase 3
Veramyst
GSKPreclinical
Xolair
RochePreclinical
Nucala
GGlaxo Dba Glaxosmithkline
Preclinical
Celexa
AbbViePreclinical
Atrovent
Boehringer IngelheimPreclinical
Tylenol
KKenvue Brands
Preclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
DUPIXENT
RegeneronPreclinical
Blood Withdrawn
Emergent BioSolutionsPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Seasonal Allergic Rhinitis3 trials
A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis(SAR).
Active, not recruiting·GGenrix (Shanghai) Biopharmaceutical Co., Ltd.·Phase 2·NCT06315426·240 enrolled
Chronic Rhinosinusitis With Nasal Polyps2 trials
The Study of GR1802 in Patients with Chronic Rhinosinusitis with Nasal Polyps
Active, not recruiting·GGenrix (Shanghai) Biopharmaceutical Co., Ltd.·Phase 2·NCT05873803·70 enrolled
Sinusitis1 trial
A Study of GR1802 in Participants With Chronic Sinusitis With Nasal Polyps
Active, not recruiting·GGenrix (Shanghai) Biopharmaceutical Co., Ltd.·Phase 3·NCT06516302·228 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for GR1802. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details